PharmaDrug Inc. announced that David Kideckel will be joining the board effective immediately. David joins PharmaDrug after nearly 20 years of combined industry and capital markets experience, most recently serving as Managing Director, Senior Institutional Equity Research Analyst at ATB Capital Markets. David's industry experience spans several senior healthcare &biotechnology executive roles including at Johnson &Johnson Inc. and Alexion Pharmaceuticals (acquired by AstraZeneca).